

Evaluation of cellular, acellular, and matrix-like products (CAMPs) in the management of nonhealing diabetic foot ulcers: an interim analysis of the STABLECAMP trial

Thomas E Serena,¹ MD | Brianna Tramelli¹ | Emily King¹ MS | Dereck Shi,¹ MS | Madison Dunn¹ | Manisha Mehta² DPM | David Simon,³ DPM FACFAS | R. Andrew Pavelescu,⁴ DPM, FACFAS, FRCPS(Glas)

¹SerenaGroup Inc., Cambridge, MA, USA; ²GFC of Southeastern Michigan, Detroit, MI, USA; ³Mount Sinai Brooklyn Hospital, Brooklyn, NY, USA; ⁴The Foot, Ankle, & Vein Specialists, Venice, FL 34293, USA

Correspondence: Brianna Tramelli (btramelli@serenagroups.com)

Received: 6 October 2025 | **Accepted:** 22 October 2025

Funding: The STABLECAMP trial was conducted under a grant from Stability Biologics®, LLC.

Keywords: Cellular, acellular and matrix-like products | interim analysis | chronic wounds | diabetic foot ulcer | clinical trial design

Abstract

Background: Diabetic foot ulcers (DFUs) are chronic wounds associated with high morbidity, mortality, and economic burden. Current standard of care (SOC) achieves less than optimal healing rates, highlighting the need for novel and cost-effective therapies.

Methods: An interim analysis of this multicenter, prospective, randomized controlled modified platform clinical trial evaluated the efficacy of multiple cellular, acellular, and matrix-like products (CAMPs) with SOC versus SOC alone. The primary endpoint was percentage of target ulcers achieving complete wound closure in 12 weeks, defined as 100% re-epithelialization without drainage for two consecutive weeks, confirmed by blinded independent review.

Results: In Intent-To-Treat (ITT), the dual layer amnion/chorion membrane allograft (DLACG) with SOC arm achieved a 58.3% closure rate versus 13.3% with SOC alone, a 45% absolute gain that was statistically significant (n=12, 95% CI 15.7% to 68.4%, p=0.001, $\alpha=0.05$). All other treatment groups were not significant in the ITT population. In Per Protocol (PP), analysis of the four-layer amniotic membrane allograft (FLAG) with SOC arm achieved a 63.6% closure rate versus 23.8% with SOC alone, a 39.8% absolute gain that was statistically significant (n=11, 95% CI 4.5% to 64.8%, p=0.027, $\alpha=0.05$). All other treatment arms were not significant in PP population. Additionally, the percent area reduction (PAR) from TV-1 to TV-13 measured weekly with digital photographic planimetry, using an imaging device, and physical examination were analyzed. For ITT and PP populations, all treatment arms outperformed SOC on average and median wound-area reduction. For PP, demographic summary statistics were analyzed to determine randomized baseline balance across groups, which was achieved with no statistically significant differences between groups at the time of interim analysis.

Conclusion: The interim analysis revealed that the placental membranes products trended toward superiority over SOC. The statistical significance in the ITT population for DLACG suggests that this product is superior to SOC.

Introduction

Type 2 diabetes accounts for the majority of the more than 500 million cases of diabetes worldwide.¹ The increasing prevalence of type 2 diabetes is driven by modifiable risk factors including obesity, poor metabolic health, sedentary lifestyles, tobacco use, and alcohol consumption.² Among its most debilitating complications are diabetic foot ulcers (DFUs), which arise from factors such as excessive plantar pressure, poorly fitting footwear, gait abnormalities, and repetitive trauma.³ DFU evaluation and classification typically consider ulcer size, depth, infection severity, presence of peripheral neuropathy or peripheral arterial disease, and anatomical location.⁴

DFUs affect an estimated 19–34% of individuals with diabetes and are associated with a five-year mortality rate of 50–70%.³ Standard of care (SOC) for DFUs include sharp debridement, offloading, reduction in bacterial load and maintenance of moisture balance. However, SOC heals less than 50% of DFUs in 12 weeks.⁵ Prevention through regular screening, often requiring co-ordination between primary and specialist care, is a central management strategy but is associated with high costs.⁶ In the United States alone, the economic burden of diabetic foot disease was estimated at \$80 billion in 2017.⁷ Outcomes are disproportionately poor among patients of lower socioeconomic status, with limited access to advanced wound care, particularly in minority communities.⁸ Despite the clinical and economic impact, chronic wound research remains underfunded, with only 0.17% of the \$7 billion allocated by the U.S. National Institutes of Health between 2002 and 2011 directed towards DFU research.⁹

Advanced wound management incorporates cellular, acellular, and matrix-like products (CAMPs), defined as 'a broad category of biomaterials, synthetic materials, or biosynthetic matrices that support the repair or regeneration of injured tissues through various mechanisms of action'.¹⁰ CAMPs offer multiple therapeutic benefits, including protection of the wound environment, coverage of exposed deep structures, facilitation of surgical closure, and improvements in both functional outcomes and cosmetic appearance.¹⁰

The STABLECAMP clinical trial employed a modified master trial design – platform – to evaluate multiple CAMP products within a single overarching protocol. A variation of this platform design was published in 2025.¹¹ The initial phase will include five CAMPs, three of which are included in this interim analysis. The platform design provides flexibility for the addition or removal of products based on the analysis of data.

A platform is an adaptive clinical trial design that allows the simultaneous evaluation of multiple interventions against a common control group. It is ideally suited for the study of multiple CAMP products. In addition, unlike traditional randomized controlled trials (RCTs), which assess a fixed set of treatments over a defined period, platform trials enable new treatments to be added or ineffective ones to be dropped over time based on interim analyses. This trial was a dual platform design, for which we have coined the term "Matriarch". The Matriarch design includes two different wound types. In this case DFU and VLU. This analysis focuses only on the DFU side of the Matriarch. At this point, not all of the products have been added to the trial. New products will be added following appropriate enrollment of the initially added CAMPs and an interim analysis.

Materials and methods

STABLECAMP is a multicenter, prospective, randomized controlled modified platform clinical trial designed to evaluate the efficacy of multiple cellular, acellular, and matrix-like products (CAMPs) with standard of care (SOC) compared with SOC alone for the treatment of nonhealing diabetic foot ulcers (DFUs) (clinicaltrials.gov #NCT06560502). The protocol initially specifies five CAMPs for evaluation; however, the adaptive nature of the platform design permits the addition of new investigational products contingent upon data analysis and protocol amendments. The interim analysis evaluated three of the five planned test products. This study was conducted at 21 SerenaGroup, Inc. or affiliated centers throughout the United States with 229 patients with nonhealing DFUs enrolled. Enrollment for this study began October 2024 and interim analysis was conducted August 2025. The study population was drawn from patients with DFUs who were attending wound clinics.

Objectives and endpoints

The primary objective for the STABLECAMP clinical trial was to determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing DFUs and venous leg ulcers (VLUs) with multiple CAMPs with SOC versus SOC alone over 12 weeks. The primary endpoint was the percentage of target ulcers achieving complete wound closure in 12 weeks.

An additional important endpoint evaluated was percentage wound area reduction (PAR) from TV-1 to TV-13 measured weekly with digital photographic planimetry, using a digital imaging device, and physical examination.

Diagnosis

The diagnosis of DFUs is primarily clinical and relies on a thorough patient history, comprehensive physical

TABLE 1 | Product details

Product name	Key features
AmnioCore	Dual layer, amniotic membrane allograft (DLAG)
Amnio Tri-Core	Three-layer, amniotic membrane allograft (TLAG)
Amnio Quad-Core	Four-layer, amniotic membrane allograft (FLAG)
AmnioCore Pro	Dual layer, amnion/chorion membrane allograft (DLACG)
AmnioCore Pro+	Three-layer, amnion/chorion/amnion membrane allograft (TLACG)

examination, and selective diagnostic testing. DFUs typically develop on weight-bearing areas of the foot, most commonly the plantar surface of the metatarsal heads, and are often preceded by evidence of peripheral neuropathy and peripheral arterial disease (PAD). Neuropathic ulcers generally present with a callused rim, punched out appearance, and varying amounts of granulation tissue, whereas is-chemic or neuroischemic ulcers frequently have irregular margins, pale or necrotic wound beds, and minimal exudate. Pain perception is often reduced or absent due to sensory neuropathy but may be pronounced in cases complicated by ischemia or infection.

A detailed clinical history is essential to differentiate DFUs from other chronic wound types. Key elements include duration of diabetes and level of glycemic control, history of previous ulcerations or amputations, presence of peripheral vascular disease, neuropathic symptoms, mechanical or traumatic causes of injury, prior wound treatments, and footwear habits. Differential diagnoses that must be excluded included venous leg ulcers, arterial ulcers unrelated to diabetes, pressure injuries, vasculitic lesions, and malignant ulcers.

Additionally, a neurological assessment was performed to evaluate loss of protective sensation. All potential subjects underwent vascular screening. Ankle brachial index (ABI) was the most employed assessment. Patients with an ABI >0.7 met the inclusion criteria. Values greater than 1.3 necessitated additional evaluation. In patients with in-compressible, calcified arteries (common in long-standing diabetes), alternative methods such as toe-brachial index (TBI), with values ≥0.6 indicating adequate perfusion. A transcutaneous oxygen measurement (TCOM) ≥40mmHg indicating adequate perfusion also satisfied the inclusion criteria.

Vulnerable populations

Although vulnerable subjects were not specifically recruited for this study, vulnerable subjects were present in the potential subject pool.

Product description

This study evaluated five products: dual layer amniotic membrane allograft (DLAG), three-layer amniotic membrane allograft (TLAG), four-layer amniotic membrane allo-graft (FLAG), dual-layer amnion/chorion membrane allograft (DLACG), and three-layer amnion/chorion/amnion membrane allograft (TLACG). All these products were intended for homologous use as a barrier and applied as a covering to offer protection from the surrounding environment. The products were provided sterilized in an inner peel pouch, within a non-sterile outer peel pouch, within a carton. All products are comprised of donated human tissue of which donor eligibility determinations, recovery, processing, storage, testing, and distribution are performed in accordance with 21 CFR Part 1271 and States regulations as well as AATB standards. For the interim analysis, only DLAG, FLAG, and DLACG were evaluated. Table 1 describes the features of each product.

Subject characteristics

Patients with nonhealing DFUs were recruited for this study from participating wound clinics. Once patients agreed to adhere to the study schedule, and read and signed the IRB approved Informed Consent Form, screening was conducted to determine whether subjects were eligible based on the in-clusion and exclusion criteria, listed in Table 2.

Study procedures

Participants underwent a structured sequence of clinical visits including screening, treatment, healing confirmation, and follow-up phases to ensure accurate eligibility assessment, standardized wound care, consistent intervention delivery, and reliable endpoint determination. Subjects were evaluated weekly (± 3 days) over a 12-week treatment period, with any additional dressing changes recorded as unscheduled visits and abbreviated assessments were performed when needed.

This is an open access article under the terms of the Creative Commons BY-NC-ND license, which enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

TABLE 2 | Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
• Must be at least 21 years of age or older. • Must have a diagnosis of type 1 or 2 diabetes. • At randomization, must have a target ulcer with a minimum surface area of 1.0cm² and a maximum surface area of 5.0cm² measured post debridement. • Target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit. • Target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus. • Target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle, provided it is below the medial aspect of the malleolus. • Affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable: ◦ ABI between 0.7 and ≤1.3; ◦ TBI ≥0.6; ◦ TCOM ≥40mmHg; ◦ PVR: biphasic. • If two or more ulcers are present, they must be separated by at least 2cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. • Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment. • Must consent to using the prescribed offloading method for the duration of the study. • Must agree to attend the weekly study visits required by the protocol. • Must be willing and able to participate in the informed consent process.	• Known to have a life expectancy of <6 months. • Target ulcer is not secondary to diabetes. • Target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin. • Target ulcer exposes tendon or bone. • Evidence of osteomyelitis complicating the target ulcer. • Receiving immunosuppressants (including systemic corticosteroids at doses greater than 10mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics). • Applied topical steroids to the ulcer surface within one month of initial screening. • The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer. • Has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit. • Surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit. • The surface area measurement of the target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC. • Has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer. • Pregnant or considering becoming pregnant within the next 6 months. • Has end stage renal disease requiring dialysis. • Participation in a clinical trial involving treatment with an investigational product within the previous 30 days. • Has a medical or psychological condition that may interfere with study assessments. • Treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit. • Has a malnutrition indicator score <17 as measured on the Mini Nutritional Assessment. • Has a disorder that would pose an unacceptable risk of post-operative complications.

Participants who did not meet the eligibility criteria at initial screening but were subsequently determined eligible were re-consented and assigned a new screening number. Up to three screening attempts were allowed, and those who subsequently met all inclusion and no exclusion criteria were enrolled. At the screening visit conducted approximately 14 days prior to enrollment, informed consent was obtained, followed by a review of medical history to assess eligibility based on the inclusion and exclusion criteria. Demographic data (including height, weight, BMI, sex, and ethnicity), medical and medication histories, and current use of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids were recorded.

A vascular screening test was performed unless recent results (≤3 months) were available. Vital signs were measured, and a general physical examination was conducted.

Additional assessments included the Mini Nutritional Assessment (MNA), HbA1c testing (unless available within 3 months), and condition-specific evaluations: Wagner grade, Fitzpatrick skin type, pain intensity via a visual analogue scale (VAS), and de-tailed wound characterization (granulation tissue, nonviable tissue, depth, exudate, and peri-wound skin). Historical wound measurements from two weeks prior to screening were collected; a reduction in wound

TABLE 3 | Study schedule

	SV	TV-1	TV-2, TV-3	TV-4	TV-5, TV-6, TV-7	TV-8	TV-9, TV-10, TV-11	TV-12	TV-13	CCV
Window period	-14	Day 0	Week 1, week 2	Week 3	Week 4, Week 5, Week 6	Week 7	Week 8 Week 9 Week 10	Week 11	Week 12	14+
Record medical history and demographic information	X									
Assessment of eligibility	X	X								
Sign informed consent form	X									
Vascular screening test	X									
Physical exam	X	X								
Mini Nutrition Assessment	X									
HbA1c	X									
Wagner Grade	X									
Fitzpatrick Scale	X									
Historical measurement	X									
Randomization		X								
Assessment for AE and SAE		X	X	X	X	X	X	X	X	X
Review medication for changes		X	X	X	X	X	X	X	X	X
Vital signs	X	X	X	X	X	X	X	X		
Wound assessment	X	X	X	X	X	X	X	X	X	X
Pain assessment (VAS)	X	X	X	X	X	X	X	X	X	X
wQOL		X		X		X		X	X	
FWS		X		X		X		X	X	
Study ulcer cleaning, de- bridement (if applicable)	X	X	X	X	X	X	X	X	X	
Study ulcer area with digital images	X	X	X	X	X	X	X	X	X	X
Treatment based on randomization		X	X	X	X	X	X	X		
Apply dressing	X	X	X	X	X	X	X	X	X	
Offloading	X	X	X	X	X	X	X	X		

size of >20% during this historical run-in period resulted in screen failure.

During the two-week active screening phase, SOC wound management was provided, consisting of cleansing with

normal sterile saline (NSS), sharp debridement, post-debridement ulcer photography and measurement using a digital imaging device, and application of calcium alginate or foam dressing. Patients also initiated trial-specific offloading with a protective ambulatory brace or, if not tolerated, a total contact cast (TCC), with four weeks of documented off-loading required before enrollment.

At the enrollment/randomization visit (treatment visit (TV) 1; Day 0), eligibility was reconfirmed, adverse events and medication changes were reviewed, and a symptom-directed physical examination was performed. The percentage area reduction (PAR) from the screening period was assessed to confirm it remained <25%. Vital signs, wound characteristics, VAS pain scores, Forgotten Wound Score (FWS), and Wound Quality of Life (wQOL) questionnaire were completed. Eligible participants were randomized to receive either CAMP with SOC or SOC alone. Wounds were cleansed with NSS, debrided, photographed, and measured using a digital imaging device before treatment. Dressings were applied as per protocol, with optional absorptive dressings for highly exudative wounds upon medical monitor approval. Patients not using TCC were assessed for ad-herence to offloading.

Participants returned weekly (TV-2 to TV-12) for safety and efficacy monitoring, including review of adverse events, medication changes, vital signs, wound assessment, pain scoring, and questionnaire administration (FWS and wQOL at TV-4, TV-8, and TV-12). Wound cleansing, debridement, measurement, and treatment per randomization arm were repeated at each visit.

At the final treatment visit (TV-13) or earlier if wound closure occurred, adverse events, medication changes, pain, and quality-of-life measures (FWS, wQOL) were recorded. For unhealed ulcers, wound characteristics were documented, and follow-up care was arranged.

Healing was confirmed at a dedicated visit 14±3 days after the first observation of complete re-epithelialization without drainage. This visit included adverse event review, medication update, pain assessment, investigator confirmation of closure, ulcer photog-raphy and measurement, and independent blinded verification. Early withdrawals underwent procedures equivalent to the final visit when possible. Unscheduled visits were conducted as needed for adverse event evaluation, medication review, and dressing changes.

At study exit, participants with unhealed wounds were transitioned back to physician-directed SOC. Independent healing confirmation was performed by two blinded wound care specialists reviewing de-identified eKare images from closure and confirmation visits. Disagreements between reviewers were resolved in favor of the assessment aligning with the principal investigator's determination. [Table 3](#) details the schedule of events for the study.

Subject withdrawal

All participants had the right to withdraw from the study at any time during the treatment period without prejudice. The completion status of each participant's in-volvement in the clinical trial was documented. In the event that study treatment or protocol-required observations were discontinued for any participant, the reason(s) for discontinuation were recorded. The investigator had the authority to withdraw a participant from the study at any time if deemed medically necessary. Whenever feasible, the reason for withdrawal or early termination was documented.

A participant was classified as lost to follow-up if they could not be reached after five telephone contact attempts and three written communications.

Subject compensation

Participants received a nominal compensation of \$50 USD upon completion of each study visit. This compensation was intended to offset expenses associated with participation, including travel, parking, and the additional time re-quired for study-specific procedures and data collection.

Results

A total of 138 DFU patients from 21 sites were included in the interim analysis. Overall, 45 patients received standard of care alone, 50 patients received DLAG with SOC, 12 patients received DLACG with SOC, and 31 patients received FLAG with SOC. Nineteen patients from all treatment groups are considered ongoing at the time of interim analysis. Fourteen patients were discontinued during the study and 46 were excluded during screening. Summary statistics on demographic variables are provided in [Table 4](#) and [Table 5](#).

No statistically significant differences were observed across treatment groups (all $p>0.05$), suggesting that randomization achieved adequate baseline balance. Wound area and wound age were used as stratification factors in the trial design, and at this interim analysis, they are summarized descriptively to assess balance. The reported p-values are exploratory checks of randomization balance and were not used to adjust the interim analysis endpoints.

TABLE 4 | Demographic summary statistics by treatment group

Variable	Standard of care	DLAG	DLACG	FLAG	P-value
Age (Years)					
N (Mean)	45 (62.1)	50 (63.2)	12 (61.8)	31 (59.4)	0.641
Sex, N (%)					
Male	31 (68.8)	36 (72.0)	9 (75.0)	20 (64.5)	0.67
Female	14 (31.1)	14 (28.0)	3 (25.0)	11 (35.4)	
Wagner Grade, N (%)					
Grade 0 – No ulcer	1 (2.2)	0 (0)	0 (0)	0 (0)	0.276
Grade 1 – Superficial ulcer	36 (80.0)	39 (78.0)	6 (50.0)	24 (77.4)	
Grade 2 – Deep ulcer	8 (17.7)	11 (22.0)	6 (50.0)	7 (22.5)	
Grade 3 – Ulcer + Cellulitis/osteomyelitis	0 (0)	0 (0)	0 (0)	0 (0)	
Grade 4 – Localized gangrene	0 (0)	0 (0)	0 (0)	0 (0)	
Grade 5 – Extensive gangrene	0 (0)	0 (0)	0 (0)	0 (0)	
Ethnicity N (%)					
American Indian/Alaskan Native	0 (0)	0 (0)	0 (0)	0 (0)	0.06
Asian	1 (2.2)	0 (0)	0 (0)	0 (0)	
Black	8 (17.7)	17(34.0)	1 (8.3)	4 (12.9)	
Pacific Islander	0 (0)	1 (2)	0 (0)	0 (0)	
White	36 (80.0)	31 (62.0)	9 (75.0)	23 (74.1)	
Other	0 (0)	1 (2)	2 (16.6)	4 (12.9)	
Current tobacco use, N (%)					
Yes	5 (11.1)	3 (6.0)	1 (8.3)	3 (9.6)	0.65
No	40 (88.8)	47 (94.0)	11 (91.6)	28 (90.3)	

TABLE 5 | Stratification summary statistics

Variable	Standard of care (n=45)	DLAG (n=50)	DLACG (n=12)	FLAG (n=31)	P-value
Wound area, N (%)					
Less than 2cm ²	20 (44.4)	21 (42.0)	7 (58.3)	16 (51.6)	0.452
Between 2cm ² and 3cm ²	12 (26.6)	19 (38.0)	1 (8.3)	9 (29.0)	
Greater than 3cm ²	13 (28.8)	10 (20.0)	4 (33.3)	6 (19.3)	
Wound age, N (%)					
Wound >60 days	8 (17.7)	9 (18.0)	3 (25.0)	9 (29.0)	0.516
Wound <60 days	37 (82.2)	41 (82.0)	9 (75.0)	22 (70.9)	

TABLE 6 | Percent Area Reduction (PAR) summary statistics without outliers for ITT

Treatment arm	N	Mean	Standard deviation	Median	IQR
Standard of Care	44	47.29	41.03	45.00	85.22
DLAG with SOC	49	60.56	37.34	70.00	61.90
DLACG with SOC	10	91.18	16.79	100.00	6.00
FLAG with SOC	31	62.07	39.54	76.92	51.54

TABLE 7 | Percent Area Reduction (PAR) summary statistics without outliers for PP

Treatment arm	N	Mean	Standard deviation	Median	IQR
Standard of Care	21	75.10	29.65	77.27	31.82
DLAG with SOC	26	77.48	29.51	96.16	40.48
DLACG with SOC	9	90.21	17.50	100.00	8.00
FLAG with SOC	11	75.78	41.46	100.00	31.85

The primary endpoint was assessed for the interim analysis. The primary endpoint is the percentage of target ulcers achieving complete wound closure in 12 weeks. The intent-to-treat (ITT) and per protocol (PP) populations were analyzed.

In the ITT population, DLAG with SOC arm achieved a 26% closure rate versus 13.3% with SOC alone, a 12.7% absolute gain that was not statistically significant (n=50, 95% CI -3.7% to 28%, p=0.123, α=0.05). The DLACG with SOC arm achieved a 58.3% closure rate versus 13.3% with SOC alone, a 45% absolute gain that was statistically significant (n=12, 95% CI 15.7% to 68.4%, p=0.001, α=0.05). The FLAG with SOC arm achieved a 21.9% closure rate versus 13.3% with SOC alone, a 8.6% absolute gain that was not statistically significant (n=32, 95% CI -8.3% to 26.8%, p=0.324, α=0.05).

Among the PP population, DLAG with SOC arm achieved a 44.4% closure rate versus 23.8% with SOC alone, a 20.6% absolute gain that was not statistically significant (n=27, 95% CI -6.5% to 43.1%, p=0.138, α=0.05). The DLACG with SOC arm achieved a 50% closure rate versus 23.8% with SOC alone, a 26.2% absolute gain that was not statistically significant (n=10, 95% CI -7.7% to 55.6%, p=0.145, α=0.05). The FLAG with SOC arm achieved a 63.6% closure rate versus 23.8% with SOC alone, a 39.8% absolute gain that was statistically significant (n=11, 95% CI 4.5% to 64.8%, p=0.027, α=0.05).

Additionally, the percent area reduction (PAR) from TV-1 to TV-13 measured weekly with digital photographic planimetry, using an imaging device, and physical examination were analyzed.

Within each arm, any individual PAR value falling below Q1 – 1.5*IQR or above Q3 + 1.5*IQR was flagged and excluded. For ITT, all treatment groups outperformed Standard of Care on both average and median wound-area reduction, with



FIGURE 1 | Digital images from SV-1, TV-1, and HCV (left to right), DLAG with SOC treatment arm. The patient gave consent for the publication of images.

This is an open access article under the terms of the Creative Commons BY-NC-ND license, which enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

summary statistics for each treatment group (without outliers) reported in [Table 6](#).

For PP, DLACG with SOC and FLAG with SOC outperformed SOC alone on both average and median wound-area reduction, with summary statistics for each treatment group (without outliers) reported in [Table 7](#).

Sequential images shown in [Figure 1](#) document the trajectory of wound healing from SV-1, TV-1, and HCV in a patient assigned to the DLAG with SOC treatment arm.

SOC patients were offered a separate rescue trial if they failed to heal. The long-term durability trials are separate from the main trial.

Discussion

Interim analysis included a data lock on the electronic data capture (EDC) system and quality assurance review prior to data analysis. The purpose of this interim analysis is to determine balance across treatment groups and comparison to current standard of care for the primary endpoint and PAR. Patients were stratified by wound area and wound age. There is no significant difference between strata across all treatment groups, therefore, the randomization scheme achieved a balanced baseline. Additional analysis by the stratification group is planned for the final analysis.

For the primary endpoint, DLACG with SOC was statistically significant in the ITT population, however, was not statistically significant in the PP population. The small differences in sample size between populations may influence the results of the Chi-squared test, and additional enrollment will occur until the planned sample size is met for all treatment groups.

Percent area reduction provides insight into the closure rates by treatment group. In the ITT population, all treatment groups achieved a higher mean area reduction than SOC, while in the PP population DLACG with SOC and FLAG with SOC achieved a higher mean area reduction than SOC. This provides a promising result at interim and confirmation of the clinical trial design prior to final analysis.

Conclusion

In conclusion, the interim analysis revealed that the placental membranes products trended toward superiority over SOC. The statistical significance in the ITT population for DLACG suggests that this product is superior to SOC and once all of the ongoing patients complete, the product can be removed from the platform and replaced with a new product. The success of the placental membranes in this trial suggests that response adjusted randomization should be considered to reduce the number of patients in the SOC group.

Informed consent statement

Informed consent was obtained from all subjects involved in the study.

Data availability statement

The data is proprietary but is available on request to the corresponding author.

Conflicts of interest

The authors declare no conflicts of interest. The funders of the STABLE-CAMP study had no role in the design of the study; in the writing of this manuscript, or in the decision to publish the results.

Declaration of generative AI

During the preparation of this work the authors used OpenAI to support drafting and language refinement of portions of this manuscript, including improving clarity, grammar, and flow. The AI tool was not used for data generation, data analysis, interpretation of results, or drawing scientific conclusions. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Author contributions

Conceptualization, TS; methodology, TS, BT, EK and D.Shi; data curation, D.Shi; writing—original draft preparation, TS, BT, EK and D.Shi; writing—review and editing, TS, BT and EK; visualization, MM, D Simon and RAP; project administration, MD. All authors have read and agreed to the published version of the manuscript.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. <https://www.diabetesatlas.org> (accessed 25 October 2025)
2. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment

- and prevention. *Int J Med Sci*. 2014;11(11):1185-1200. <https://doi.org/10.7150/ijms.10001>
3. McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. *Diabetes Care*. 2023;46(1):209-221. <https://doi.org/10.2337/dci22-00434>
 4. Game F. Classification of diabetic foot ulcers. *Diabetes Metab Res Rev*. 2016;32 Suppl 1:186-194. <https://doi.org/10.1002/dmrr.2746>
 5. Fife CE, Eckert KA, Carter MJ. Publicly reported wound healing rates: the fantasy and the reality. *Adv Wound Care (New Rochelle)*. 2018;7(3):77-94. <https://doi.org/10.1089/wound.2017.0743>
 6. Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. *J R Soc Med*. 2017;110(3):104-109. <https://doi.org/10.1177/0141076816688346>
 7. Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. *J Foot Ankle Res*. 2020;13(1):16. <https://doi.org/10.1186/s13047-020-00383-2>
 8. Ha JH, Jin H, Park JU. Association between socioeconomic position and diabetic foot ulcer outcomes: a population-based cohort study in South Korea. *BMC Public Health*. 2021;21(1):1395. <https://doi.org/10.1186/s12889-021-11406-3>
 9. Armstrong DG, Kanda VA, Lavery LA, Marston W, Mills JL Sr, Boulton AJ. Mind the gap: disparity between research funding and costs of care for diabetic foot ulcers. *Diabetes Care*. 2013;36(7):1815-1817. <https://doi.org/10.2337/dc12-2285>
 10. Wu S, Carter M, Cole W, et al. Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs). *J Wound Care*. 2023;32(Sup4b):S1-S31. <https://doi.org/10.12968/jowc.2023.32.Sup4b.S1>